| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced that the first patient was treated with [212Pb]PSV359 in a second cohort of the Company's Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha (FAP-α). Patients are being selected for [212Pb]PSV359 targeted alpha particle therapy by SPECT imaging with [203Pb]PSV359.
Patients in this cohort are receiving [212Pb]PSV359 at 5.0 mCi for up to four doses every eight weeks. The Safety Monitoring Committee (SMC) recommended evaluating [212Pb]PSV359 at a higher dose based on its review of two patients dosed with [212Pb]PSV359 at 2.5 mCi alone.
Posted In: CATX
